Moderna, Inc.
A biotechnology company that uses messenger RNA (mRNA) to build medicines and vaccines, best known for Spikevax, its COVID-19 vaccine. Founded in 2010 in Cambridge, Massachusetts, it grew out of the venture-building firm Flagship Pioneering with help from scientists including MIT's Robert Langer. Its name blends "modified" and "RNA"—and conveniently hides the word "modern."
Granted 769.3K · Bought 160.3K · Sold 26.4K
Granted 33.1K · Sold 660.9K
Granted 382.4K · Sold 451.1K
Bought 31.6K
Granted 146.3K · Sold 31.0K
Granted 128.0K · Sold 10.8K
Granted 12.2K
Granted 732
Granted 17.9K
Granted 17.2K
Granted 18.6K · Sold 6.5K
Granted 9.6K
Granted 4.1K
Granted 2.3K · Sold 1.1K
| Insider | Stake change | Holds now | Granted / vested | Bought | Sold |
|---|---|---|---|---|---|
| Bancel StephaneChief Executive Officer, Director · 11 transactions | — | 48.36M | 769.3K | 160.3K | 26.4K |
| Afeyan NoubarDirector · 166 transactions | — | 6.86M | 33.1K | — | 660.9K |
| Hoge StephenPresident · 98 transactions | -6.1% | 1.64M | 382.4K | — | 451.1K |
| Sagan PaulDirector · 1 transaction | — | 494.1Kas of Mar 2025 | — | 31.6K | — |
| Klinger Shannon ThymeChief Legal Officer · 96 transactions | +1116.5% | 79.3K | 146.3K | — | 31.0K |
| Mock James MChief Financial Officer · 79 transactions | — | 71.4K | 128.0K | — | 10.8K |
| Nader FrancoisDirector · 1 transaction | +59.1% | 32.8K | 12.2K | — | — |
| Berenson StephenDirector · 1 transaction | +3.4% | 22.2Kas of May 2024 | 732 | — | — |
| Nabel Elizabeth GDirector · 3 transactions | +1306.9% | 19.3K | 17.9K | — | — |
| Horning SandraDirector · 2 transactions | +1253.6% | 18.6K | 17.2K | — | — |
| Hussain AbbasDirector · 6 transactions | — | 12.1K | 18.6K | — | 6.5K |
| Rubenstein David M.Director · 3 transactions | — | 9.6K | 9.6K | — | — |
| Tallett Elizabeth EDirector · 1 transaction | +577.2% | 4.8K | 4.1K | — | — |
| Garay ArpaChief Commercial Officer · 4 transactions | +44.9% | 3.7Kas of Dec 2023 | 2.3K | — | 1.1K |
Select a row to see that insider’s individual transactions. Sum of the holdings confirmed in the 12 months before this insider's last filing. A Form 4 reports a holding per line — held directly, or through a named trust, partnership or foundation, and in each share class separately — never a person’s total. Lines not restated in that time are left out and shown apart: an active filer restates what they still hold, so a line they did not restate is more often an entity since renamed, whose shares a successor line reports too. An amber marker means some were left out.
Net open-market activity over the last 3 years: -995.9K shares. Grants, option exercises and tax withholding are excluded — they are compensation mechanics, not decisions to buy or sell.